Articles

Numerous new innovations in stem-cell transplantation are coming to the market. In this session, experts offer the clinician, manufacturer, and payer perspectives regarding these new therapies.

As one of the largest operational oncology value-based payment models, OCM has been a driving force in cancer

Cancer care is complex and expensive, making a one-size-fits-all approach to drug benefit designs and coverages an unfavorable solution for patients with cancer. In this session, panelists discuss drug benefit reforms and the intended and unintended consequences of the recommended provisions.

With multiple stakeholders playing a key role in value-based contracting, the pharmaceutical industry faces many obstacles. In this session, experts discuss these obstacles and the strategies for overcoming them.

340B is a discount program for low-income areas that increases resources and allows for patient expansion. In this session, panelists discuss the accuracy of pricing, the current state of the program, and future developments.

In this session, industry leaders discuss defining clinical utility for genomic testing and make recommendations to ensure appropriate implementation in cancer care.

Technology can enhance the patient engagement experience, creating a willingness among patients to receive advice and counseling virtually. In this session, experts discuss the challenges of engaging patients and the future of technology in the healthcare system as it relates to cancer care.

No one truly knows what it is like to navigate cancer until they are diagnosed with the disease. In this session, survivors shared their stories and messages of hope as we prepare for Thanksgiving.

Depending on the stakeholder’s point of view, value-based contracting can have many definitions and meanings. In this session, experts from across the healthcare continuum explore what is working, what has failed, and what lessons have been learned regarding value-based contracting.

Designing and implementing value-based contracts is a challenge to stakeholders across the cancer care ecosystem. In this discussion, panelists analyze the future of these contracts and precision medicine.